Nventa: HspE7 effective in treatment of anal warts in men

By Lisa Kerner

Charlotte, N.C., Sept. 7 - Nventa Biopharmaceuticals Corp. said results from its phase 2 clinical trial of the therapeutic vaccine HspE7 demonstrated activity in treating anal genital warts in men, with 81% of patients showing no warts or marked improvement.

In the study, 30 men received three monthly injections of 1,500 mcg of HspE7 and were followed for 48 weeks. Response was measured by clinical assessment, photographs and measurement of warts using high-resolution anoscopy.

At week 24, three men (11%) had complete response, or absence of warts, and 18 (67%) had improved, according to the San Diego-based pharmaceutical company.

Nventa said it plans to combine HspE7 with the adjuvant Hiltonol to improve response rate or to decrease response time.

The data were presented at the 23rd International Papillomavirus Conference in Prague, Czech Republic.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.